

# Proteomics and Mass Spectrometry 2010

## The team

Stephen Barnes, PhD   Matt Renfrow, PhD   Helen Kim, PhD  
4-7117, MCLM 452   6-4681, MCLM 570   4-3880, MCLM 460A  
[sbarnes@uab.edu](mailto:sbarnes@uab.edu)   [Renfrow@uab.edu](mailto:Renfrow@uab.edu)   [helenkim@uab.edu](mailto:helenkim@uab.edu)

Jim Mobley, PhD   Jeevan Prasain, PhD   Peter E. Prevelige, PhD  
6-6363, THT 521   6-2612, MCLM 456   5-5327, BBRB 416  
[mobleyja@uab.edu](mailto:mobleyja@uab.edu)   [jprasain@uab.edu](mailto:jprasain@uab.edu)   [prevelig@uab.edu](mailto:prevelig@uab.edu)

S Barnes/H Kim BMG 744 1/05/10

## Course plan

- Meet Tuesdays/Fridays in MCLM 401 from 9-11 am (Jan 5-Mar 23)
- Graduate Students taking this course are required to attend each session (unless advance communication with instructor)
- Evaluations will be made from projects/exams
- Where possible, class notes will be available on the UAB proteomics website (go to <http://www.uab.edu/proteomics/index2.php> - click on **Class**)

S Barnes/H Kim BMG 744 1/05/10

## Recommended general texts

- **Suggested text - “*Introduction to Proteomics*”** by Daniel C. Liebler, 2002
- **Also see “*The Expanding Role of Mass Spectrometry in Biotechnology*”** by Gary Siuzdak (a 2003 edition of the 1996 first edition)
- **“*Mass spectrometry data analysis in proteomics*”,** (ed., Mathiesson, R) in *Methods in Molecular Biology*, vol 367.

S Barnes/H Kim BMG 744 1/05/10

## Suggested readings

- Kenyon G, et al. *Defining the mandate of proteomics in the post-genomics era: workshop report*. *Mol Cell Proteomics*, 1: 763-780 (2002)
- Kim H et al. *Proteomics and mass spectrometry in nutrition research*. *Nutrition*, 20: 155-165 (2004)
- Righetti P. et al. *Prefractionation techniques in proteome analysis: the mining tools of the third millennium*. *Electrophoresis*, 26: 297-319 (2005)
- Anderson NL. *The roles of multiple proteomic platforms in a pipeline for new diagnostics*. *Mol Cell Proteomics*, 4:1441-1444 (2005)
- Venkatesan et al. *An empirical framework for binary interactome mapping*. *Nat Methods*, 6:83-90 (2009) PMID: 19060904
- Yan W et al. *Evolution of organelle-associated protein profiling*. *J Proteomics*, 72:4-11 (2009) PMID: 19110081
- Pan S, et al. *Mass Spectrometry Based Targeted Protein Quantification: Methods and Applications*. *J Proteome Res*, 8:787-797 (2009) PMID: 19105742

S Barnes/H Kim BMG 744 1/05/10

## BMG/PHR 744 - section 1

- Jan 5, Tu S Barnes/H Kim  
*The world of biomolecules. The proteome, proteomics and other -omics and where to start*
- Jan 8, Fri M Renfrow  
*Mass spectrometry – gas phase transfer and instrumentation – including ETD*
- Jan 12, Tu S Barnes  
*Methods for the identification of proteins: MALDI-TOF of proteins and peptide mass fingerprinting; LC analysis and peptide sequencing*
- Jan 15, Fri S Barnes  
*Ion fragmentation in mass spectrometry; application to proteomics*
- Jan 19, Tu S Barnes  
*Isotopes in mass mass spectrometry*
- Jan 22, Fri J Prasain  
*Ion Fragmentation of small molecules; Lipidomics*
- Jan 26, Tu S Barnes  
*Sample preparation for proteomics and mass spectrometry*
- Jan 29, Fri **Mid-term take-home exam**

S Barnes/H Kim BMG 744 1/05/10

## BMG/PHR 744 - section 2

- Jan 29, Fri E Shonsey  
*Application of MS in Forensics*
- Feb 2, Tu H Kim  
*Simplifying the proteome - techniques of protein purification; protein separation by electrophoresis and other 2D-methods*
- Feb 5, Fri A Smith IV  
*Connecting proteomics into bioinformatics; MUDPIT and SEQUEST; false discovery rates in complex systems*
- Feb 9, Tu C Crasto  
*The bioinformatics of the proteome*
- Feb 12, Fri J Prasain  
*Designing metabolomics experiments*
- Feb 16, Tu S Barnes  
*Mass spectrometry in qualitative and quantitative burrowing of the proteome*
- Feb 19, Fri J Prasain  
*Qualitative and quantitative analysis/method validation*

S Barnes/H Kim BMG 744 1/05/10

## BMG/PHR 744 - section 3

- Feb 23, Tu S. Barnes  
*Enzymology and mass spectrometry*
- Feb 26, Fri M Renfrow  
*Analysis of protein-protein interactions by affinity purification and mass spectrometry*
- Mar 2, Tu P Prevelige  
*Mass Spectrometry as a Tool for Studying Protein Structure*
- Mar 5, Fri P Prevelige  
*Study of macromolecular structures – protein complexes*

S Barnes/H Kim BMG 744 1/05/10

## BMG/PHR 744 - section 4

- Mar 9, Tu C-C Wang  
*Tissue and body fluid proteomics and mass spectrometry*
- Mar 12, Fri J Mobley/D Stella  
*Applications of MS to tissue imaging*
- Mar 16, Tu M Renfrow  
*Applications of FT-ICR-MS*
- Mar 19, Fri J Novak/M Renfrow  
*Mass spectrometry in glycomics research - Application to IgA nephropathy*
- Mar 23, Tu H Kim  
*Use of proteomics and MS methods in the study of the brain proteome and neurodegenerative diseases*
- Mar 23 *Final take-home exam due*

S Barnes/H Kim BMG 744 1/05/10

## **Course learning objectives**

- **Introduction to the concepts and practice of systems biology**
- **Sample ionization and mass spectrometers**
- **Mass spectrometry and its principal methods**
  - **protein and peptide ID; peptide and metabolite ion fragmentation; stable isotope labeling; quantification**

S Barnes/H Kim BMG 744 1/05/10

## **Course learning objectives**

- **Informatics, statistics and quality control in mass spectrometry**
- **Importance of prefractionation in proteomics - 2DE, LC and arrays**
- **Applying mass spectrometry to protein modifications, function, structure and biological location, and to other biological molecules**

S Barnes/H Kim BMG 744 1/05/10

## Hopes and hazards of biomedical research

It boils down to whether having taken life apart into its distinct pieces, can we reassemble it in new ways? [*strong analogies to what have been the central quests of physics since the early 20<sup>th</sup> century*]

Can we create a form of life that might live in a very hostile extra-terrestrial environment and thereby save humanity?

Or will we (*as well as our enemies*) instead create life forms that can terrorize, or even eliminate us?  
*Will Einstein's and Oppenheimer's moral dilemmas surface in biomedical science?*

S Barnes/H Kim BMG 744 1/05/10

## History of proteomics

- Essentially preceded genomics
- “Human protein index” conceived in the 1970’s by Norman and Leigh Anderson
- The term “proteomics” coined by Marc Wilkins in 1994
- Human proteomics initiative (HPI) began in 2000 in Switzerland - <http://www.hupo.org>
- Human Proteome Organization (HUPO) had meetings in 2002 in Versailles, France; 2003 in Montreal, Canada; 2004 in Beijing, China; 2005 in Munich, Germany; 2006 in Long Beach, CA; 2007 in Seoul, Korea; 2008 in Amsterdam, The Netherlands; 2009 in Toronto, Canada. The 2010 meeting will be in Sydney, Australia.

S Barnes/H Kim BMG 744 1/05/10

## What proteomics is, what it isn't

“Proteomics is not just a mass spectrum of a spot on a gel”

George Kenyon,  
2002 National Academy of Sciences Symposium

Proteomics is the identities, quantities, structures, and biochemical and cellular functions of all proteins in an organism, organ or organelle, and how these vary in space, time and physiological state.

S Barnes/H Kim BMG 744 1/05/10

## Collapse of the single target paradigm - the need for systems biology

### Old paradigm

*Diseases are due to single genes - by knocking out the gene, or designing specific inhibitors to its protein, disease can be cured*

But the gene  
KO mouse  
didn't notice  
the loss of the  
gene



### New paradigm

*We have to understand gene and protein networks - proteins don't act alone - effective systems have built in redundancy*

S Barnes/H Kim BMG 744 1/05/10

## Research styles

- **Classical NIH R01**
  - A specific target and meaningful substrates
  - Emphasis on mechanism
  - Hypothesis-driven
  - **Linearizes locally multi-dimensional space**
- **Example**
  - Using an X-ray crystal structure of a protein to determine if a specific compound can fit into a binding pocket - from this "*a disease can be cured*" - this approach ignores whether the compound can get to the necessary biological site, whether it remains chemically intact, and where else it goes

S Barnes/H Kim BMG 744 1/05/10

## From substrates to targets to systems - a changing paradigm

- **Classical approach** - one substrate/one target
- **Mid 1980s** - use of a pure reagent to isolate DNAs from cDNA libraries (multiple targets)
- **Early 1990s** - use of a reagent library (multiple ligands) to perfect interaction with a specific target
- **2000+** - effects of specific reagents on cell systems using DNA microarrays (500+ genes change, not just one)
- **2008** - integration of transcriptomics, proteomics, peptidomics, metabolomics (everything changes, just like in ecology)

S Barnes/H Kim BMG 744 1/05/10



## Exploring information space - the *Systems Biology* approach

- **Systems biology means measuring everything about a system at the same time**
- **For a long time, it was deemed as too complex for useful or purposeful investigation**
- **But are the tools available today?**

S Barnes/H Kim BMG 744 1/05/10

## Systems Biology

*“To understand biology at the system level, we must examine the structure and dynamics of cellular and organismal function, rather than the characteristics of isolated parts of a cell or organism.”*

*“Properties of systems, such as robustness, emerge as central issues, and understanding these properties may have an impact on the future of medicine.”*

*“However, many breakthroughs in experimental devices, advanced software, **and analytical methods** are required before the achievements of systems biology can live up to their much-touted potential.”*

**Kitano, 2002**

S Barnes/H Kim BMG 744 1/05/10

## The Biological Data of the Future

- Destructive
- Qualitative
- Uni-dimensional
  
- Low temporal resolution
- Low data density
- Variable standards
- Non cumulative

Current nature of data

- Non-destructive
- Quantitative
- Multi-dimensional and spatially resolved
- **High Temporal resolution**
- High data density
- Stricter standards
- Cumulative

Elias Zerhouni, FASEB 2004

S Barnes/H Kim BMG 744 1/05/10

## Techniques in Systems Biology

- DNA microarrays to describe and *quantify* the transcriptosome
- Large scale and small scale proteomics
- Protein arrays
- Protein structure
- Metabolomics
- Integrated computational models

S Barnes/H Kim BMG 744 1/05/10

## Papers on systems biology

<http://www.nature.com/focus/systemsbiology/userguide/index.html>


This is a cluster of papers in Nature Cell Biology, Nature Reviews in Molecular and Cell Biology, and Molecular Systems Biology that was published in October, 2006

S Barnes/H Kim BMG 744 1/05/10

## High dimensionality of microarray or proteomics data means you must understand statistics

While reproducible data can be obtained, the large numbers of parameters (individual genes or proteins) require large changes in expression before a change can be regarded as significant

Use of the Bonferroni correction:  
A conservative correction



S Barnes/H Kim BMG 744 1/05/10

## Properties of a system and fold-change

- The primary assumption of most users of DNA microarrays (and proteomics) has been that the cut-off for assessing change is two-fold
- This is a very naïve view of properties of a system
  - Barnes' law “Fold-change is inversely related to biological importance”

S Barnes/H Kim BMG 744 1/05/10

## Properties of a system and fold-change

- For a system, items that are important are the least likely to change
  - when they do, catastrophic events may occur
  - Proliferation vs apoptosis (PTEN < 50% change)
- Items unimportant to the system can vary a lot (not a core value)
- How can we perceive “importance”?
  - Re-weight the data by dividing by the variance
  - Need to have enough information about each item to calculate its variance ( $n > 5$ )

S Barnes/H Kim BMG 744 1/05/10

## Vulnerability of a system

- To really understand biological systems, you have to appreciate their dynamic state
  - Read about control theory
  - Realize that systems are subject to rhythms
  - Subject them to fourier transform analysis to detect their resonance (requires far more data than we can currently collect)
- A small signal at the right frequency can disrupt the system
  - Analogies “the small boy in the bath” and “the screech of chalk on a chalk board”

S Barnes/H Kim BMG 744 1/05/10

## Hazards of interpreting microarray (proteomic) data

- “Expression patterns are the place where environmental variables and genetic variation come together. Environmental variables will affect gene expression levels.”
- “Don’t we need to be very careful to understand the environmental inputs that might have an impact on that expression? Perhaps an over-the-counter herbal supplement might cause an expression pattern that looks like that of a very aggressive tumor.”

Abridged from Karen Kline, 2002


S Barnes/H Kim BMG 744 1/05/10

## Why study the proteome when we can do DNA microarrays?



- DNA microarray analysis allows one to examine the mRNA levels of thousands and thousands of genes
- However, the correlation between gene expression and protein levels is often poor, although that may be an issue of the timing of sampling
- Is this a new finding? No, before the age of molecular biology, it was well known

S Barnes/H Kim BMG 744 1/05/10

## Apparent structured relationship between gene expression and protein content




S Barnes/H Kim BMG 744 1/05/10



## Sampling time affects interpretation of correlation between mRNA and protein expression for important proteins

Determining the relationship between mRNA (red) and protein (blue) levels depends totally on when you measure them - for the figure opposite, the ratio at 2.5 hr is 10:1, whereas at 7.5 hr it's 1:100

- better to measure the ratio over time and integrate the area under the curve



S Barnes/H Kim BMG 744 1/05/10

(Barnes & Allison, 2004)

## Defining disease from the proteome


- Numerous examples of a revised picture of disease from analysis of the proteome
  - Aging
  - Cancer
  - Cardiovascular disease
  - Neurodegeneration
- Infectious disease and the microbial proteome

S Barnes/H Kim BMG 744 1/05/10




## Upregulation of a gene for a crucial protein may have poor correlation at the protein level: example A.

- May be manifested as little or no change in amount, because the cell “damps” out the change.



S Barnes/H Kim BMG 744 1/05/10

## Gene expression data may predict the nature of protein modifications, *but not which proteins are modified.*



S Barnes/H Kim BMG 744 1/05/10

## **Summary: Why do we need to do broad scale “proteomics”?**

- **When you don’t have a clue;**
- **When you have only a very small clue;**  
i.e. you’ve done a microarray experiment, and you have a list of 3,284 genes that are differentially regulated in your system;
- **When you knock out a gene (and hence a protein) that you’re convinced is essential for life and health, and the animal pees as usual.**

S Barnes/H Kim BMG 744 1/05/10

## **Rationales for proteomics approaches in today’s research**

- **Identify a “marker” protein(s);**
  - Cancer detection/Monitor response to chemotherapy
  - Identify one pathogen from others;
  - Distinguish a virulent strain of pathogen from nonvirulent.
- **Characterize protein differences between disease and normal tissues--**
  - For understanding the disease process;
  - To develop drug targets;
- **In cancer, there may be novel proteins due to chromosome instability (ETV6-ABL and BCR-ABL), or inappropriate expression may occur (proteins from embryonic or fetal stages of development)**

S Barnes/H Kim BMG 744 1/05/10

**Where there is pathology, but the genetic basis unknown, proteomics can have critical role in identifying proteins to target for therapeutic intervention**

**Two major disease examples:**

- HIV: protease is targeted today;
  - are there other proteins, either viral or host, that could be targeted to better deal with the disease?
- Alzheimer's disease: 3 known mutations (APP, PS1, PS2) and risk factors (ApoE, estrogen loss);
  - 50% of AD patients do not have any of the known genetic abnormalities, yet all become demented, all have amyloid plaques and NFT in their brains.
  - Remember, every AD patient has AD 100%.

S Barnes/H Kim BMG 744 1/05/10

**Challenges in proteomics**

- So many protein forms! How many 100-mers are possible using 20 different amino acids?
- Can protein forms be predicted from genomic sequence data?
  - Posttranslational modifications
  - Differential splicing
  - Unknown transcriptional mechanisms
- The dynamic range ( $>10^9$ )
- No equivalent to the PCR reaction
  - Avogadro's number

S Barnes/H Kim BMG 744 1/05/10

## Avogadro's number comes back to haunt us: a reality check for proteomics

- One gram-mole of anything is  $6.02 \times 10^{23}$  molecules
- For mass spec detection, we need at least 100 femtomole ( $10^{-13}$  moles) or  $6.02 \times 10^{10}$  molecules

<u>protein expression per cell</u>	<u>need # cells for 100 fmoles</u>
10	$6.02 \times 10^9$
100	$6.02 \times 10^8$
1,000	$6.02 \times 10^7$
10,000	$6.02 \times 10^6$
100,000	$6.02 \times 10^5$

S Barnes/H Kim BMG 744 1/05/10

## Central issue in proteome complexity: dynamic range

Cellular proteomes involve a very wide *dynamic range*: proteins can differ in their amounts by nine (9) orders of magnitude;

- In blood, albumin is  $0.5 \times 10^{-3}$  M, whereas cytokines are pM ( $10^{-12}$  M)
- A 2D gel that is overloaded with respect to an abundant protein, may have *barely detectable* amounts of a low abundance protein.....And if you can't see it, you don't know it's changed.


S Barnes/H Kim BMG 744 1/05/10

## The need to enrich for subproteomes, and/or isolate the lower abundant proteins

- See lecture by Helen Kim on February 2nd in section 2 of the course
- **Biological properties:**
  - Intracellular location; Protein-protein interactions; Posttranslational modifications
- **Intrinsic properties:**
  - Net charge; Size; Extent of tertiary structure; Hydrophobicity

S Barnes/H Kim BMG 744 1/05/10

## A valuable role of the proteomics approach: Discovery & analysis of protein-protein interactions



(The arrows indicate the proteins that could be antigens for immunoprecipitation of the complex.)

S Barnes/H Kim BMG 744 1/05/10

## **Experimental design and quality control issues**

- **How do we carry out a proteomics experiment?**
  - Randomize sample analysis
  - Process samples blinded to identities
  - Standardize procedures and vendors of disposable plastics used in experiment-- minimize variation where possible
  - Consult with statistician before experiment; ensure enough “power” for the experiment so that statistical analysis yields significant data.

S Barnes/H Kim BMG 744 1/05/10

## **Take home lessons in analyzing proteins with proteomics methods**

- The fewer proteins in the proteome you analyze, the better the chances of detecting the ones that “matter.”
- Genomics data can complement proteomics data.
- Understanding the biological properties of the proteins of interest can enhance proteomics analysis.
- Intrinsic properties of proteins form the basis of invaluable prefractionation prior to proteomics analysis.
- Quality control is an issue that becomes increasingly important with large datasets and measurement of small changes

S Barnes/H Kim BMG 744 1/05/10

## Predicting the proteome

- ***Bioinformatics* is the basis of high throughput proteome analysis using mass spectrometry. Protein sequences can be computationally predicted from the genome sequence**
- **However, *bioinformatics* is not able to predict with accuracy the sites or chemistry of posttranslational modifications - these need to be defined chemically (using mass spectrometry)**

S Barnes/H Kim BMG 744 1/05/10

## Predicting the proteome

- ***Predicting the proteome has elements of a circular argument***
  - protein sequences were initially determined chemically and were correlated with the early gene sequences. It then became easier to sequence a protein from its mRNA (captured from a cDNA library). This could be checked (to a degree) by comparison to peptide sequences. Now we have the human genome (actually two of them).
- ***So, is it valid to predict the genes (and hence the proteome) from the sequence of the genome?***
  - We're doing this in current research. But as we'll see, the mass spectrometer is the ultimate test of this hypothesis -
  - why? because of its mass accuracy

S Barnes/H Kim BMG 744 1/05/10

## Protein structure

- **Determined by folding - folding rules not yet defined - cannot predict structure *de novo***
- **X-ray crystallography has been used to produce elegant structural information**
- **NMR and H-D exchange combined with mass spec enable the in-solution structure to be determined (see Peter Prevelige's lectures on March 2/5)**

S Barnes/H Kim BMG 744 1/05/10

## Protein informatics

- **The predicted sequences of the proteins encoded by genes in sequenced genomes are available in many publicly available databases (subject to the limitations mentioned earlier)**
- **The mass of the protein is less useful (for now) than the masses of its fragment ions - as we'll see later, the masses of tryptic peptides can be used to identify a protein in a matter of seconds**

S Barnes/H Kim BMG 744 1/05/10



## **So, what do we do with all these data?**

- **Management of the data generated by DNA microarray and proteomics/protein arrays**
  - High dimensional analysis
- **Beyond the capabilities of individual investigators**
- **Urgent need for visualization tools**
- **The importance of new statistical methods for analysis of high dimensional systems**

S Barnes/H Kim BMG 744 1/05/10

## **PROTIG and Videocast**

- **There is an NIH-based proteomics interest group (PROTIG)**
  - Sign up at <http://proteome.nih.gov>
- **Proteomics and mass spec talks are available for viewing (using Real Player)**
  - Log on at <http://videocast.nih.gov>
  - Podcasts are also available

S Barnes/H Kim BMG 744 1/05/10